CySEC’s 2016 Customer Due Diligence Directive- 144-2007-08(Α) – seriously raising the bar (ISX : ASX)
Paradigm Pharmaceuticals (ASX: PAR) conducting a clinical trial on the use of PPS to treat bone marrow oedema – Channel 7 News story
You must be logged in to post a comment.